The Experts below are selected from a list of 11238 Experts worldwide ranked by ideXlab platform
William R Wagner - One of the best experts on this subject based on the ideXlab platform.
-
synthesis characterization and paclitaxel release from a biodegradable elastomeric poly ester urethane urea bearing phosphorylcholine groups for reduced thrombogenicity
Biomacromolecules, 2012Co-Authors: Yi Hong, Sang Ho Ye, Anca L Pelinescu, William R WagnerAbstract:Biodegradable polymers with high elasticity, low thrombogenicity, and Drug loading capacity continue to be pursued for vascular engineering applications, including vascular grafts and stents. A biodegradable elastomeric polyurethane was designed as a candidate material for use as a Drug-eluting stent coating, such that it was nonthrombogenic and could provide Antiproliferative Drug release to inhibit smooth muscle cell proliferation. A phosphorylcholine containing poly(ester urethane) urea (PEUU-PC) was synthesized by grafting aminated phosphorylcholine onto backbone carboxyl groups of a polyurethane (PEUU-COOH) synthesized from a soft segment blend of polycaprolactone and dimethylolpropionic acid, a hard segment of diisocyanatobutane and a putrescine chain extender. Poly(ester urethane) urea (PEUU) from a soft segment of polycaprolactone alone was employed as a control material. All of the synthesized polyurethanes showed high distensibility (>600%) and tensile strengths in the 20–35 MPa range. PEUU-PC e...
-
synthesis characterization and paclitaxel release from a biodegradable elastomeric poly ester urethane urea bearing phosphorylcholine groups for reduced thrombogenicity
Biomacromolecules, 2012Co-Authors: Yi Hong, Sang Ho Ye, Anca L Pelinescu, William R WagnerAbstract:Biodegradable polymers with high elasticity, low thrombogenicity, and Drug loading capacity continue to be pursued for vascular engineering applications, including vascular grafts and stents. A biodegradable elastomeric polyurethane was designed as a candidate material for use as a Drug-eluting stent coating, such that it was nonthrombogenic and could provide Antiproliferative Drug release to inhibit smooth muscle cell proliferation. A phosphorylcholine containing poly(ester urethane) urea (PEUU-PC) was synthesized by grafting aminated phosphorylcholine onto backbone carboxyl groups of a polyurethane (PEUU-COOH) synthesized from a soft segment blend of polycaprolactone and dimethylolpropionic acid, a hard segment of diisocyanatobutane and a putrescine chain extender. Poly(ester urethane) urea (PEUU) from a soft segment of polycaprolactone alone was employed as a control material. All of the synthesized polyurethanes showed high distensibility (>600%) and tensile strengths in the 20–35 MPa range. PEUU-PC e...
Yi Hong - One of the best experts on this subject based on the ideXlab platform.
-
synthesis characterization and paclitaxel release from a biodegradable elastomeric poly ester urethane urea bearing phosphorylcholine groups for reduced thrombogenicity
Biomacromolecules, 2012Co-Authors: Yi Hong, Sang Ho Ye, Anca L Pelinescu, William R WagnerAbstract:Biodegradable polymers with high elasticity, low thrombogenicity, and Drug loading capacity continue to be pursued for vascular engineering applications, including vascular grafts and stents. A biodegradable elastomeric polyurethane was designed as a candidate material for use as a Drug-eluting stent coating, such that it was nonthrombogenic and could provide Antiproliferative Drug release to inhibit smooth muscle cell proliferation. A phosphorylcholine containing poly(ester urethane) urea (PEUU-PC) was synthesized by grafting aminated phosphorylcholine onto backbone carboxyl groups of a polyurethane (PEUU-COOH) synthesized from a soft segment blend of polycaprolactone and dimethylolpropionic acid, a hard segment of diisocyanatobutane and a putrescine chain extender. Poly(ester urethane) urea (PEUU) from a soft segment of polycaprolactone alone was employed as a control material. All of the synthesized polyurethanes showed high distensibility (>600%) and tensile strengths in the 20–35 MPa range. PEUU-PC e...
-
synthesis characterization and paclitaxel release from a biodegradable elastomeric poly ester urethane urea bearing phosphorylcholine groups for reduced thrombogenicity
Biomacromolecules, 2012Co-Authors: Yi Hong, Sang Ho Ye, Anca L Pelinescu, William R WagnerAbstract:Biodegradable polymers with high elasticity, low thrombogenicity, and Drug loading capacity continue to be pursued for vascular engineering applications, including vascular grafts and stents. A biodegradable elastomeric polyurethane was designed as a candidate material for use as a Drug-eluting stent coating, such that it was nonthrombogenic and could provide Antiproliferative Drug release to inhibit smooth muscle cell proliferation. A phosphorylcholine containing poly(ester urethane) urea (PEUU-PC) was synthesized by grafting aminated phosphorylcholine onto backbone carboxyl groups of a polyurethane (PEUU-COOH) synthesized from a soft segment blend of polycaprolactone and dimethylolpropionic acid, a hard segment of diisocyanatobutane and a putrescine chain extender. Poly(ester urethane) urea (PEUU) from a soft segment of polycaprolactone alone was employed as a control material. All of the synthesized polyurethanes showed high distensibility (>600%) and tensile strengths in the 20–35 MPa range. PEUU-PC e...
Sang Ho Ye - One of the best experts on this subject based on the ideXlab platform.
-
synthesis characterization and paclitaxel release from a biodegradable elastomeric poly ester urethane urea bearing phosphorylcholine groups for reduced thrombogenicity
Biomacromolecules, 2012Co-Authors: Yi Hong, Sang Ho Ye, Anca L Pelinescu, William R WagnerAbstract:Biodegradable polymers with high elasticity, low thrombogenicity, and Drug loading capacity continue to be pursued for vascular engineering applications, including vascular grafts and stents. A biodegradable elastomeric polyurethane was designed as a candidate material for use as a Drug-eluting stent coating, such that it was nonthrombogenic and could provide Antiproliferative Drug release to inhibit smooth muscle cell proliferation. A phosphorylcholine containing poly(ester urethane) urea (PEUU-PC) was synthesized by grafting aminated phosphorylcholine onto backbone carboxyl groups of a polyurethane (PEUU-COOH) synthesized from a soft segment blend of polycaprolactone and dimethylolpropionic acid, a hard segment of diisocyanatobutane and a putrescine chain extender. Poly(ester urethane) urea (PEUU) from a soft segment of polycaprolactone alone was employed as a control material. All of the synthesized polyurethanes showed high distensibility (>600%) and tensile strengths in the 20–35 MPa range. PEUU-PC e...
-
synthesis characterization and paclitaxel release from a biodegradable elastomeric poly ester urethane urea bearing phosphorylcholine groups for reduced thrombogenicity
Biomacromolecules, 2012Co-Authors: Yi Hong, Sang Ho Ye, Anca L Pelinescu, William R WagnerAbstract:Biodegradable polymers with high elasticity, low thrombogenicity, and Drug loading capacity continue to be pursued for vascular engineering applications, including vascular grafts and stents. A biodegradable elastomeric polyurethane was designed as a candidate material for use as a Drug-eluting stent coating, such that it was nonthrombogenic and could provide Antiproliferative Drug release to inhibit smooth muscle cell proliferation. A phosphorylcholine containing poly(ester urethane) urea (PEUU-PC) was synthesized by grafting aminated phosphorylcholine onto backbone carboxyl groups of a polyurethane (PEUU-COOH) synthesized from a soft segment blend of polycaprolactone and dimethylolpropionic acid, a hard segment of diisocyanatobutane and a putrescine chain extender. Poly(ester urethane) urea (PEUU) from a soft segment of polycaprolactone alone was employed as a control material. All of the synthesized polyurethanes showed high distensibility (>600%) and tensile strengths in the 20–35 MPa range. PEUU-PC e...
Anca L Pelinescu - One of the best experts on this subject based on the ideXlab platform.
-
synthesis characterization and paclitaxel release from a biodegradable elastomeric poly ester urethane urea bearing phosphorylcholine groups for reduced thrombogenicity
Biomacromolecules, 2012Co-Authors: Yi Hong, Sang Ho Ye, Anca L Pelinescu, William R WagnerAbstract:Biodegradable polymers with high elasticity, low thrombogenicity, and Drug loading capacity continue to be pursued for vascular engineering applications, including vascular grafts and stents. A biodegradable elastomeric polyurethane was designed as a candidate material for use as a Drug-eluting stent coating, such that it was nonthrombogenic and could provide Antiproliferative Drug release to inhibit smooth muscle cell proliferation. A phosphorylcholine containing poly(ester urethane) urea (PEUU-PC) was synthesized by grafting aminated phosphorylcholine onto backbone carboxyl groups of a polyurethane (PEUU-COOH) synthesized from a soft segment blend of polycaprolactone and dimethylolpropionic acid, a hard segment of diisocyanatobutane and a putrescine chain extender. Poly(ester urethane) urea (PEUU) from a soft segment of polycaprolactone alone was employed as a control material. All of the synthesized polyurethanes showed high distensibility (>600%) and tensile strengths in the 20–35 MPa range. PEUU-PC e...
-
synthesis characterization and paclitaxel release from a biodegradable elastomeric poly ester urethane urea bearing phosphorylcholine groups for reduced thrombogenicity
Biomacromolecules, 2012Co-Authors: Yi Hong, Sang Ho Ye, Anca L Pelinescu, William R WagnerAbstract:Biodegradable polymers with high elasticity, low thrombogenicity, and Drug loading capacity continue to be pursued for vascular engineering applications, including vascular grafts and stents. A biodegradable elastomeric polyurethane was designed as a candidate material for use as a Drug-eluting stent coating, such that it was nonthrombogenic and could provide Antiproliferative Drug release to inhibit smooth muscle cell proliferation. A phosphorylcholine containing poly(ester urethane) urea (PEUU-PC) was synthesized by grafting aminated phosphorylcholine onto backbone carboxyl groups of a polyurethane (PEUU-COOH) synthesized from a soft segment blend of polycaprolactone and dimethylolpropionic acid, a hard segment of diisocyanatobutane and a putrescine chain extender. Poly(ester urethane) urea (PEUU) from a soft segment of polycaprolactone alone was employed as a control material. All of the synthesized polyurethanes showed high distensibility (>600%) and tensile strengths in the 20–35 MPa range. PEUU-PC e...
Eric O. Aboagye - One of the best experts on this subject based on the ideXlab platform.
-
phosphorylation status of thymidine kinase 1 following Antiproliferative Drug treatment mediates 3 deoxy 3 18f fluorothymidine cellular retention
PLOS ONE, 2014Co-Authors: Roberta Sala, Quangde Nguyen, Chirag B K Patel, David J Mann, Joachim H G Steinke, Ramon Vilar, Eric O. AboagyeAbstract:Background 3′-Deoxy-3′-[18F]-fluorothymidine ([18F]FLT) is being investigated as a Positron Emission Tomography (PET) proliferation biomarker. The mechanism of cellular [18F]FLT retention has been assigned primarily to alteration of the strict transcriptionally regulated S-phase expression of thymidine kinase 1 (TK1). This, however, does not explain how anticancer agents acting primarily through G2/M arrest affect [18F]FLT uptake. We investigated alternative mechanisms of [18F]FLT cellular retention involving post-translational modification of TK1 during mitosis.
-
3 deoxy 3 18f fluorothymidine as a new marker for monitoring tumor response to Antiproliferative therapy in vivo with positron emission tomography
Cancer Research, 2003Co-Authors: Henryk Barthel, Marcel C Cleij, David R Collingridge, Clyde O Hutchinson, Safiye Osman, Sajinder K Luthra, Frank Brady, P B Price, Eric O. AboagyeAbstract:3′-Deoxy-3′-[ 18 F]fluorothymidine ([ 18 F]FLT) has been proposed as a new marker for imaging tumor proliferation by positron emission tomography (PET). The uptake of [ 18 F]FLT is regulated by cytosolic S-phase-specific thymidine kinase 1 (TK1). In this article, we have investigated the use of [ 18 F]FLT to monitor the response of tumors to Antiproliferative treatment in vivo . C3H/Hej mice bearing the radiation-induced fibrosarcoma 1 tumor were treated with 5-fluorouracil (5-FU; 165 mg/kg i.p.). Changes in tumor volume and biodistribution of [ 18 F]FLT and 2-[ 18 F]fluoro-2-deoxy-d-glucose ([ 18 F]FDG) were measured in three groups of mice ( n = 8–12/group): ( a ) untreated controls; ( b ) 24 h after 5-FU; and ( c ) 48 h after 5-FU. In addition, dynamic [ 18 F]FLT-PET imaging was performed on a small animal scanner for 60 min. The metabolism of [ 18 F]FLT in tumor, plasma, liver, and urine was determined chromatographically. Proliferation was determined by staining histological sections for proliferating cell nuclear antigen (PCNA). Tumor levels of TK1 protein and cofactor (ATP) were determined by Western blotting and bioluminescence, respectively. Tumor [ 18 F]FLT uptake decreased after 5-FU treatment (47.8 ± 7.0 and 27.1 ± 3.7% for groups b and c , respectively, compared with group a ; P 18 F]FLT uptake was significantly more pronounced than that of [ 18 F]FDG. The PET image data confirmed lower tumor [ 18 F]FLT retention in group c compared with group a , despite a trend toward higher radiotracer delivery for group c . Other than phosphorylation in tumors, [ 18 F]FLT was found to be metabolically stable in vivo . The decrease in tumor [ 18 F]FLT uptake correlated with the PCNA-labeling index ( r = 0.71, P = 0.031) and tumor volume changes after 5-FU treatment ( r = 0.58, P = 0.001). In this model system, the decrease in [ 18 F]FLT uptake could be explained by changes in catalytic activity but not translation of TK1 protein. Compared with group a , TK1 levels were lower in group b (78.2 ± 5.2%) but higher in group c (141.3 ± 9.1%, P a to b to c ( P 18 F]FLT and PET. In our model system, the radiotracer uptake was correlated with PCNA-labeling index. The decrease in [ 18 F]FLT uptake after 5-FU was more pronounced than that of [ 18 F]FDG. [ 18 F]FLT is, therefore, a promising marker for monitoring Antiproliferative Drug activity in oncology that warrants additional testing.